NASDAQ:TYRA

Tyra Biosciences (TYRA) Stock Forecast, Price & News

$14.53

+0.77 (+5.60%)

(As of 06/2/2023 ET)

Compare

Today's Range: $13.01
▼
$14.54
50-Day Range: $11.99
▼
$16.22
52-Week Range: $4.93
▼
$16.86

Volume: 23,925 shs
Average Volume: 24,315 shs
Market Capitalization: $618.40 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $21.00

Tyra Biosciences MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 44.5% Upside
$21.00 Price Target
Short Interest: Bearish
8.03% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.65
Based on 2 Articles This Week
Insider Trading: Selling Shares
$414,171 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($1.39) to ($1.83) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.94 out of 5 stars

Medical Sector

658th out of 983 stocks

Pharmaceutical Preparations Industry

325th out of 486 stocks

3.5

Analyst's Opinion

Consensus Rating
Tyra Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $21.00, Tyra Biosciences has a forecasted upside of 44.5% from its current price of $14.53.
Amount of Analyst Coverage
Tyra Biosciences has only been the subject of 1 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
8.03% of the float of Tyra Biosciences has been sold short.
Short Interest Ratio / Days to Cover
Tyra Biosciences has a short interest ratio ("days to cover") of 41.7, which indicates bearish sentiment.
Change versus previous month
Short interest in Tyra Biosciences has recently decreased by 0.69%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Tyra Biosciences does not currently pay a dividend.
Dividend Growth
Tyra Biosciences does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for TYRA.

2.6

News and Social Media Coverage

News Sentiment
Tyra Biosciences has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Tyra Biosciences this week, compared to 1 article on an average week.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Tyra Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $414,171.00 in company stock.
Percentage Held by Insiders
18.40% of the stock of Tyra Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
84.60% of the stock of Tyra Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Tyra Biosciences are expected to decrease in the coming year, from ($1.39) to ($1.83) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Tyra Biosciences is -11.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Tyra Biosciences is -11.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Tyra Biosciences has a P/B Ratio of 2.48. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Tyra Biosciences (NASDAQ:TYRA) Stock

Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.

Receive TYRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tyra Biosciences and its competitors with MarketBeat's FREE daily newsletter.

TYRA Stock News Headlines

June 3, 2023 | americanbankingnews.com

Tyra Biosciences (NASDAQ:TYRA) Shares Gap Down to $14.47

June 1, 2023 | seekingalpha.com

Tyra Biosciences: Early Stage Developer Of Novel FGFR3-Selective Molecules

June 4, 2023 | Behind the Markets (Ad)

Laser breakthrough could send stock soaring 2,467%

Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...

May 25, 2023 | americanbankingnews.com

Tyra Biosciences (NASDAQ:TYRA) Trading Down 4.7%

May 24, 2023 | americanbankingnews.com

Tyra Biosciences (NASDAQ:TYRA) Shares Gap Down to $14.45

May 23, 2023 | finance.yahoo.com

What Makes Tyra Biosciences, Inc. (TYRA) a Good Fit for 'Trend Investing'

May 22, 2023 | finance.yahoo.com

Wall Street Analysts Believe Tyra Biosciences, Inc. (TYRA) Could Rally 59.17%: Here's is How to Trade

May 17, 2023 | americanbankingnews.com

Tyra Biosciences (NASDAQ:TYRA) Shares Gap Down to $12.40

June 4, 2023 | Behind the Markets (Ad)

Laser breakthrough could send stock soaring 2,467%

May 8, 2023 | markets.businessinsider.com

Where Tyra Biosciences Stands With Analysts

May 5, 2023 | marketwatch.com

Tyra Biosciences Reports First Quarter 2023 Financial Results and Highlights

May 5, 2023 | markets.businessinsider.com

H.C. Wainwright Keeps Their Buy Rating on Tyra Bioscience (TYRA)

April 29, 2023 | americanbankingnews.com

Tyra Biosciences (NASDAQ:TYRA) Trading 21.5% Higher

April 15, 2023 | americanbankingnews.com

Tyra Biosciences (NASDAQ:TYRA) Trading Up 8%

April 7, 2023 | americanbankingnews.com

Tyra Biosciences (NASDAQ:TYRA) Shares Gap Down to $15.67

April 6, 2023 | americanbankingnews.com

Tyra Biosciences, Inc. (NASDAQ:TYRA) COO Sells $32,320.00 in Stock

April 1, 2023 | americanbankingnews.com

Tyra Biosciences, Inc. (NASDAQ:TYRA) CEO Todd Harris Sells 2,407 Shares

March 30, 2023 | americanbankingnews.com

Insider Selling: Tyra Biosciences, Inc. (NASDAQ:TYRA) COO Sells 2,187 Shares of Stock

March 30, 2023 | americanbankingnews.com

Tyra Biosciences, Inc. (NASDAQ:TYRA) COO Daniel Bensen Sells 8,048 Shares

March 30, 2023 | americanbankingnews.com

Todd Harris Sells 2,779 Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) Stock

March 29, 2023 | finance.yahoo.com

Tyra Biosciences to Participate in Upcoming Investor Conferences

March 29, 2023 | americanbankingnews.com

Tyra Biosciences (NASDAQ:TYRA) Sets New 52-Week High at $16.00

March 29, 2023 | americanbankingnews.com

Q1 2023 EPS Estimates for Tyra Biosciences, Inc. (NASDAQ:TYRA) Boosted by HC Wainwright

March 28, 2023 | americanbankingnews.com

Oppenheimer Research Analysts Cut Earnings Estimates for Tyra Biosciences, Inc. (NASDAQ:TYRA)

March 27, 2023 | finance.yahoo.com

Here's Why 'Trend' Investors Would Love Betting on Tyra Biosciences, Inc. (TYRA)

March 26, 2023 | americanbankingnews.com

Tyra Biosciences, Inc. (NASDAQ:TYRA) CEO Sells $64,688.00 in Stock

March 26, 2023 | americanbankingnews.com

Tyra Biosciences' (TYRA) Buy Rating Reiterated at HC Wainwright

See More Headlines

TYRA Price History

30 days | 90 days | 365 days | Advanced Chart

TYRA Company Calendar

Last Earnings: 3/22/2023
Today: 6/04/2023
Next Earnings (Estimated): 8/03/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:TYRA
CUSIP: N/A
CIK: 1863127
Web: www.tyra.bio
Phone: 619-728-4760
Fax: N/A
Employees: 25
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $21.00
High Stock Price Forecast: $25.00
Low Stock Price Forecast: $17.00
Forecasted Upside/Downside: +44.5%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.25)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-55,330,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -19.89%
Return on Assets: -19.32%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 67.00
Quick Ratio: 67.00

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $5.85 per share
Price / Book: 2.48

Miscellaneous

Outstanding Shares: 42,560,000
Free Float: 34,731,000
Market Cap: $618.40 million
Optionable: Not Optionable
Beta: 0.89

Key Executives

Dr. Todd Harris Ph.D. (Age 43)
Pres, CEO, Sec., Treasurer & Director
Comp: $612.72k

Dr. Ronald V. Swanson Ph.D. (Age 59)
Chief Scientific Officer
Comp: $536.19k

Dr. Hiroomi Tada M.D. (Age 58)
Ph.D., Chief Medical Officer
Comp: $519.65k

Mr. Daniel Bensen (Age 47)
Co-Founder & COO

Lynn Scherm
Fin. Director

Ms. Esther van den Boom CPA (Age 42)
CPA, Chief Financial Officer

Dr. Robert L. Hudkins Ph.D. (Age 67)
Chief Technology Officer

Mr. Ali D. Fawaz J.D.
Gen. Counsel & Sec.

Ms. Sarah Honig
VP of Corp. Devel. & Strategy

Dr. Piyush R. Patel Ph.D. (Age 57)
Chief Devel. Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

TYRA Stock - Frequently Asked Questions

Should I buy or sell Tyra Biosciences stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tyra Biosciences in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" TYRA shares.
View TYRA analyst ratings or view top-rated stocks.
What is Tyra Biosciences' stock price forecast for 2023?: 2 equities research analysts have issued twelve-month target prices for Tyra Biosciences' stock. Their TYRA share price forecasts range from $17.00 to $25.00. On average, they predict the company's stock price to reach $21.00 in the next twelve months. This suggests a possible upside of 44.5% from the stock's current price.
View analysts price targets for TYRA or view top-rated stocks among Wall Street analysts.
How have TYRA shares performed in 2023?: Tyra Biosciences' stock was trading at $7.60 at the beginning of 2023. Since then, TYRA stock has increased by 91.2% and is now trading at $14.53.
View the best growth stocks for 2023 here.
When is Tyra Biosciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our TYRA earnings forecast.
How were Tyra Biosciences' earnings last quarter?: Tyra Biosciences, Inc. (NASDAQ:TYRA) issued its quarterly earnings results on Wednesday, March, 22nd. The company reported ($0.31) earnings per share for the quarter, topping analysts' consensus estimates of ($0.35) by $0.04.
When did Tyra Biosciences IPO?: (TYRA) raised $100 million in an initial public offering (IPO) on Wednesday, September 15th 2021. The company issued 6,700,000 shares at $14.00-$16.00 per share.

What is Tyra Biosciences' stock symbol?: Tyra Biosciences trades on the NASDAQ under the ticker symbol "TYRA."
Who are Tyra Biosciences' major shareholders?: Tyra Biosciences' stock is owned by a number of institutional and retail investors. Top institutional investors include BVF Inc. IL (7.61%), FMR LLC (7.40%), BlackRock Inc. (1.57%), Geode Capital Management LLC (0.67%), State Street Corp (0.55%) and JPMorgan Chase & Co. (0.45%). Insiders that own company stock include Boxer Capital, Llc, Daniel Bensen, Mva Investors, Llc and Todd Harris.
View institutional ownership trends.
How do I buy shares of Tyra Biosciences?: Shares of TYRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Tyra Biosciences' stock price today?: One share of TYRA stock can currently be purchased for approximately $14.53.
How much money does Tyra Biosciences make?: Tyra Biosciences (NASDAQ:TYRA) has a market capitalization of $618.40 million. The company earns $-55,330,000.00 in net income (profit) each year or ($1.25) on an earnings per share basis.
How can I contact Tyra Biosciences?: Tyra Biosciences' mailing address is 2656 STATE STREET, CARLSBAD CA, 92008. The official website for the company is www.tyra.bio. The company can be reached via phone at 619-728-4760 or via email at aconrad@tyra.bio..

This page (NASDAQ:TYRA) was last updated on 6/4/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Tyra Biosciences (TYRA) Stock Forecast, Price & News

Tyra Biosciences MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Company Ownership

Earnings and Valuation

About Tyra Biosciences (NASDAQ:TYRA) Stock

TYRA Stock News Headlines

TYRA Price History

TYRA Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

TYRA Stock - Frequently Asked Questions

Overall MarketRank^™